Search Results - "Kosovec, Juliann E."

The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation by Kelly, Ronan J, Zaidi, Ali H, Smith, Matthew A, Omstead, Ashten N, Kosovec, Juliann E, Matsui, Daisuke, Martin, Samantha A, DiCarlo, Christina, Werts, E Day, Silverman, Jan F, Wang, David H, Jobe, Blair A

“…OBJECTIVE:The aim of this study was to assess the impact of chemoradiation on the immune microenvironment to influence and optimally design future neoadjuvant…”
Get full text

ASO Visual Abstract: Comparing Survival After Resection, Ablation, and Radiation in Small Intrahepatic Cholangiocarcinoma by Masoud, Sabran J., Rhodin, Kristen E., Kanu, Elishama, Bao, Jiayin, Eckhoff, Austin M., Bartholomew, Alex J., Howell, Thomas C., Aykut, Berk, Kosovec, Juliann E., Palta, Manisha, Befera, Nicholas T., Kim, Charles Y., Herbert, Garth, Shah, Kevin N., Nussbaum, Daniel P., Blazer, Dan G., Zani, Sabino, Allen, Peter J., Lidsky, Michael E.

Get full text

High yield reproducible rat model recapitulating human Barrett’s carcinogenesis by Matsui, Daisuke, Omstead, Ashten N, Kosovec, Juliann E, Komatsu, Yoshihiro, Lloyd, Emily J, Raphael, Hailey, Kelly, Ronan J, Zaidi, Ali H, Jobe, Blair A

“…AIM To efficiently replicate the biology and pathogenesis of human esophageal adenocarcinoma(EAC) using the modified Levrat model of end-to-side…”
Get full text

The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy by Kosovec, Juliann E, Zaidi, Ali H, Pounardjian, Tamar S, Jobe, Blair A

“…Esophageal adenocarcinoma (EAC) is a lethal cancer requiring improved screening strategies and treatment options due to poor detection methods, aggressive…”
Get full text

MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model by Zaidi, Ali H, Saldin, Lindsey T, Kelly, Lori A, Bergal, Linda, Londono, Ricardo, Kosovec, Juliann E, Komatsu, Yoshihiro, Kasi, Pashtoon M, Shetty, Amit A, Keane, Timothy J, Thakkar, Shyam J, Huleihel, Luai, Landreneau, Rodney J, Badylak, Stephen F, Jobe, Blair A

“…To establish a miRNA signature for metastasis in an animal model of esophageal adenocarcinoma (EAC). The incidence of esophageal adenocarcinoma (EAC) has…”
Get full text

Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium by Malhotra, Usha, Zaidi, Ali H, Kosovec, Juliann E, Kasi, Pashtoon M, Komatsu, Yoshihiro, Rotoloni, Christina L, Davison, Jon M, R, Clint, Irvin, Hoppo, Toshitaka, Nason, Katie S, Kelly, Lori A, Gibson, Michael K, Jobe, Blair A

“…Survivin is an inhibitor of apoptosis and its over expression is associated with poor prognosis in several malignancies. While several studies have analyzed…”
Get full text

Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model by Kosovec, Juliann E, Zaidi, Ali H, Komatsu, Yoshihiro, Kasi, Pashtoon M, Cothron, Kyle, Thompson, Diane V, Lynch, Edward, Jobe, Blair A

“…To assess the reliability of magnetic resonance imaging (MRI) for detection of esophageal cancer in the Levrat model of end-to-side esophagojejunostomy. The…”
Get full text

Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma by Sweeney, Ryan, Omstead, Ashten N, Fitzpatrick, John T, Zheng, Ping, Gorbunova, Anastasia, Grayhack, Erin E, Goel, Arul, Khan, Alisha F, Kosovec, Juliann E, Wagner, Patrick L, Jobe, Blair A, Kelly, Ronan J, Zaidi, Ali H

“…Esophageal adenocarcinoma (EAC) is a leading cause of cancer-related mortality. Sitravatinib is a novel multi-gene tyrosine kinase inhibitor (TKI) that targets…”
Get full text

Comparing Survival After Resection, Ablation, and Radiation in Small Intrahepatic Cholangiocarcinoma by Masoud, Sabran J., Rhodin, Kristen E., Kanu, Elishama, Bao, Jiayin, Eckhoff, Austin M., Bartholomew, Alex J., Howell, Thomas C., Aykut, Berk, Kosovec, Juliann E., Palta, Manisha, Befera, Nicholas T., Kim, Charles Y., Herbert, Garth, Shah, Kevin N., Nussbaum, Daniel P., Blazer, Dan G., Zani, Sabino, Allen, Peter J., Lidsky, Michael E.

“…Background Hepatectomy is the cornerstone of curative-intent treatment for intrahepatic cholangiocarcinoma (ICC). However, in patients unable to be resected,…”
Get full text

PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model by Zaidi, Ali H, Kosovec, Juliann E, Matsui, Daisuke, Omstead, Ashten N, Raj, Moses, Rao, Rohit R, Biederman, Robert W W, Finley, Gene G, Landreneau, Rodney J, Kelly, Ronan J, Jobe, Blair A

“…OBJECTIVE:The purpose of the current study is to determine the efficacy of a PI3K/mTOR dual inhibitor, LY3023414, on established EAC in an in vivo model…”
Get full text

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model by Zaidi, Ali H, Kelly, Ronan J, Gorbunova, Anastasia, Omstead, Ashten N, Salvitti, Madison S, Zheng, Ping, Kosovec, Juliann E, Lee, Soyoung, Ayazi, Shahin, Babar, Laila, Finley, Gene G, Goel, Ajay, Jobe, Blair A

“…Esophageal adenocarcinoma (EAC) is a deadly disease with limited treatment options. STING is a transmembrane protein that activates transcription of interferon…”
Get full text

Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma by Babar, Laila, Kosovec, Juliann E, Jahangiri, Vida, Chowdhury, Nobel, Zheng, Ping, Omstead, Ashten N, Salvitti, Madison S, Smith, Matthew A, Goel, Ajay, Kelly, Ronan J, Jobe, Blair A, Zaidi, Ali H

“…Treatment options and risk stratification for esophageal adenocarcinomas (EAC) currently rely on pathological criteria such as tumor staging. However, with…”
Get full text

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease by Kosovec, Juliann E, Zaidi, Ali H, Omstead, Ashten N, Matsui, Daisuke, Biedka, Mark J, Cox, Erin J, Campbell, Patrick T, Biederman, Robert W W, Kelly, Ronan J, Jobe, Blair A

“…Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6…”
Get full text

Sep70/Pepsin expression in hypopharynx combined with hypopharyngeal multichannel intraluminal impedance increases diagnostic sensitivity of laryngopharyngeal reflux by Hoppo, Toshitaka, Zaidi, Ali H., Matsui, Daisuke, Martin, Samantha A., Komatsu, Yoshihiro, Lloyd, Emily J., Kosovec, Juliann E., Civitarese, Albert A., Boyd, Natalie H., Shetty, Amit, Omstead, Ashten N., Smith, Emily, Jobe, Blair A.

“…Background Improved methods of diagnosis of laryngopharyngeal reflux (LPR) would enable surgeons to better identify patients who may benefit from antireflux…”
Get full text

Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma by Matsui, Daisuke, Zaidi, Ali H, Martin, Samantha A, Omstead, Ashten N, Kosovec, Juliann E, Huleihel, Luai, Saldin, Lindsey T, DiCarlo, Christina, Silverman, Jan F, Hoppo, Toshitaka, Finley, Gene G, Badylak, Stephen F, Kelly, Ronan J, Jobe, Blair A

“…Esophageal adenocarcinoma (EAC) is an aggressive cancer necessitating the development of improved risk stratification tools for personalized care. Previously,…”
Get full text

Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma by Kosovec, Juliann E, Zaidi, Ali H, Kelly, Lori A, Rotoloni, Christina L, Vytlacil, Christopher, DiCarlo, Christina, Matsui, Daisuke, Komatsu, Yoshihiro, Boyd, Natalie H, Omstead, Ashten, Kolano, Elena L, Biederman, Robert W W, Finley, Gene, Silverman, Jan F, Landreneau, Rodney J, Jobe, Blair A

“…To assess the efficacy of heat-shock protein 90 (Hsp90) inhibitor, NVP-AUY922-AG (AUY922), in the treatment of esophageal adenocarcinoma (EAC) in vitro and in…”
Get full text

Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry by Kosovec, Juliann E., Egorin, Merrill J., Gjurich, Susanna, Beumer, Jan H.

“…5‐Fluorouracil (5‐FU) has long had a place in the treatment of many malignancies. 5‐FU plasma concentrations have been correlated with toxicity and efficacy,…”
Get full text

Prevention of Barrett Esophagus and Esophageal Adenocarcinoma by Smoothened Inhibitor in a Rat Model of Gastroesophageal Reflux Disease by Gibson, Michael K, Zaidi, Ali H, Davison, Jon M, Sanz, Alejandro F, Hough, Bruce, Komatsu, Yoshihiro, Kosovec, Juliann E, Bhatt, Astha, Malhotra, Usha, Foxwell, Tyler, Rotoloni, Christina L, Hoppo, Toshitaka, Jobe, Blair A

“…BACKGROUND:Activated hedgehog (Hh) pathway is associated with development of both Barrett esophagus (BE) and esophageal adenocarcinoma (EAC). We hypothesize…”
Get full text

Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development by Omstead, Ashten N., Kosovec, Juliann E., Matsui, Daisuke, Martin, Samantha A., Smith, Matthew A., Aaron Guel, D., Kolano, Jenna, Komatsu, Yoshihiro, Habib, Fahim, Lai, Christopher, Christopher, Kevi, Kelly, Ronan J., Zaidi, Ali H., Jobe, Blair A.

“…A rat model of surgically induced reflux recapitulates the development and progression of human esophageal adenocarcinoma (EAC). In this study, reflux was…”
Get full text

Serial Endoscopic Evaluation of Esophageal Disease in A Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development by Omstead, Ashten N, Guel, David A, Matsui, Daisuke, Kosovec, Juliann E, Martin, Samantha, Smith, Emily J, Kolano, Jenna, Campbell, Patrick, Raphael, Haley, Habib, Fahim, Christopher, Kevi, Lai, Christopher, Smith, Matthew A, Kelly, Ronan J, Zaidi, Ali H, Jobe, Blair A

Get full text